Table 2.
Summary of the included studies evaluating the presence of intestinal TG2 deposits in overt celiac disease (CD).
| Reference (first author) | Age (years), median (range) | Overt CD (n) | TG2 IgA deposits: prevalence | Diagnostic value (%) |
|---|---|---|---|---|
| Korponay- Szabo (8) | 78 (4.4–32) | 10 | 10/10 | SE: 100 |
| SP: 100 | ||||
| Salmi (12) | 42 (16–81) | 223 | 35/35 | SE: 100 |
| SP: 100 | ||||
| Koskinen (14) | 47 (4–79) | 261 | 261/261 | SE: 100 |
| SP: 82 | ||||
| Koskinen (15) | 47 (28–68) | 13 | 13/13 | SE: 100 |
| SP: 95.9 | ||||
| Kaukinen (16) | 47 (22–68) | 18 | 6/6 | SE: 100 |
| SP: 100 | ||||
| Maglio (17) | 63 (6 months–16 years) | 144 | 138/144 | SE: 95.8 |
| SP: 87.9 | ||||
| Tosco (19) | 7 | 12 | 12/12 | SE: 100 |
| SP: 80 | ||||
| Maglio (18) | <2, 15 months | <2 years: 56 | <2 years: 41/56 | SE: 73.2 |
| >2, 7 years | >2 years: 40 | >2 years: 40/40 | SE: 100 | |
| SP: ne | ||||
| Kurppa (20) | 10 (1–15) | 42 | 42/42 | SE: 100 |
| SP: ne | ||||
| Salmi (21) | 55 (20–79) | 22 EMA− | 18/18 | SE: 100 |
| 40 (16–81) | 22 EMA+ | 17/17 | SP: 100 |
SE, sensitivity; SP, specificity; ne, not evaluable (no control group).